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Abstract
Background: Heart failure remains a leading cause of mortality and a major driver of health care utilization. Despite numerous
medical advances in heart failure, associated hospitalizations continue to increase, owing largely to suboptimal outpatient
management. Remote patient monitoring (RPM) aims to further address this current need in heart failure care by providing data
to clinical teams to act pre-emptively to address clinical decompensation. However, to date, RPM approaches using noninvasive
home-based patient sensors have failed to demonstrate clinical efficacy.
Objective: The Novel Data Collection and Analytics Tools for Remote Patient Monitoring in Heart Failure (Nov-RPM-HF)
Trial aims to address current noninvasive RPM limitations. Nov-RPM-HF will evaluate a clinician co-designed RPM platform
using emerging data collection and presentation tools for heart failure management. These tools include a ballistocardiograph to
monitor nocturnal patient biometrics, clinical alerts for abnormal biometrics, and longitudinal data presentation for clinician
review.
Methods: Nov-RPM-HF is a 100-patient single-center prospective trial, evaluating patients over 6 months. The outcomes will
include patient adherence to data collection, patient/clinician-perceived utility of the RPM platform, medication changes including
the titration of guideline-directed medical therapy to target doses, heart failure symptoms/performance status, and unplanned
heart failure hospitalizations or emergency department visits.
Results: This prospective trial began enrollment in March 2020 and anticipates enrollment completion by June 2022, with trial
completion by December 2022.
Conclusions: This trial protocol aims to provide a systematic framework for the evaluation of heart failure RPM strategies,
which are currently heavily used but seldom robustly studied. The trial results will help to inform the role of noninvasive RPM
as a viable clinical management strategy in heart failure care.
International Registered Report Identifier (IRRID): DERR1-10.2196/32873
(JMIR Res Protoc 2022;11(6):e32873) doi: 10.2196/32873
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Introduction

[13], lack of clinically actionable patient data and alerts [14],
and lack of clinician engagement [15].

Heart failure (HF) remains a leading driver of morbidity and
mortality in the United States, affecting 6.5 million Americans
[1]. Despite numerous medical innovations in HF over the past
decade, per capita rates of HF hospitalizations have actually
increased from 2010 to 2017 [2]. This population is expected
to increase by 50% by 2030, placing an increasing burden on
the US health care system and highlighting the need for
innovations in HF care [3]. HF care also carries significant
economic implications, with over US $30 billion spent in direct
HF care in 2020, primarily driven by HF hospitalizations, and
estimated to double by 2030 [4-6].

The field of noninvasive RPM continues to evolve, with recent
advances in data collection and monitoring now demonstrating
improved predictive power for clinical decompensation [16].
However, there is a paucity of studies evaluating these emerging
tools as part of RPM interventions.

Effective HF care requires vigilance for indications of clinical
HF decompensation. Failure to detect and manage these
indicators can result in unplanned emergency department (ED)
visits and hospitalizations. Although patients and care teams
attempt to detect signs of impending decompensation with
conventional techniques such as daily weight measurements,
these approaches have not demonstrated consistent clinical
efficacy [7].
Optimal HF care also relies on maximizing guideline-directed
medical therapies (GDMTs). Several pharmacotherapies such
as renin-angiotensin-aldosterone system inhibitors and
beta-blockers have demonstrated mortality benefit in patients
with HF with reduced ejection fraction (HFrEF) [8,9]. However,
consistent provision of these therapies, at maximally tolerated
dosing, does not occur [10]. Logistical challenges of
conventional outpatient care contribute to this implementation
gap. These include reliance on ambulatory visits for medication
titration, which often occur months apart, and insufficient vital
sign information to allow for medication up-titration between
visits.
Remote patient monitoring (RPM) aims to address these gaps
in current HF care. RPM is a strategy that allows care teams to
monitor and manage patients outside of traditional in-person
health care encounters. The strategy could enhance current
efforts for more rapid medication titration and avoidance of
clinical decompensation and unplanned acute care visits. RPM
has demonstrated a reduction in HF hospitalizations, but only
by using an invasive hemodynamic patient sensor
(CardioMEMS) [11]. RPM strategies using noninvasive patient
sensors such as blood pressure (BP) cuffs, scales, and wearable
biosensors have reduced cost, lower risk, and greater
applicability to the HF population. However, the clinical
evidence supporting noninvasive RPM is mixed, with the
majority of clinical trials failing to demonstrate a similar clinical
benefit [12]. This lack of clinical efficacy in trials is likely
attributable to multiple factors, including poor patient adherence
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The Novel Diagnostic Tools for Remote Patient Monitoring in
Heart Failure (Nov-RPM-HF) Trial aims to address these
limitations through the design and evaluation of a novel RPM
platform for HF management that incorporates these emerging
data collection tools. The trial will evaluate the perceived utility
of the RPM platform, its impact on timely GDMT optimization
and medication changes, and its impact on unplanned ED visits
and hospitalizations.

Methods
Overview
The Nov-RPM-HF trial is a single-center prospective study of
an RPM platform and its adoption, clinical utility, and ability
to optimize GDMTs and reduce unplanned acute care events
among patients with HFrEF. Specifically, the trial will evaluate
patient adherence with passive and active data collection,
patient-perceived usability and utility of the RPM platform to
monitor their health status, clinician-perceived usability and
utility of the RPM platform for HF management, clinical utility
of the RPM clinical alerts, impact of RPM on medication
changes and titration of HF GDMT, and impact of HF RPM on
clinical outcomes (ED visits, hospitalizations).
Full inclusion and exclusion criteria are summarized in Textbox
1. Inclusion criteria include history of HFrEF with a HF
hospitalization or ED visit in the last 12 months. This criteria
selects for a HFrEF population with a baseline event rate that
mirrors the trial population in the CHAMPION (CardioMEMS
Heart Sensor Allows Monitoring of Pressure to Improve
Outcomes in NYHA Class III Heart Failure Patients) trial. Such
an event rate should allow for increased power to detect clinical
outcomes among our study population. Prior noninvasive RPM
trials have included a relatively stable population of patients
with HF with low clinical event, and this was thought to have
contributed to the inability to demonstrate clinical efficacy [13].
End-stage HF with a life expectancy <1 year or requiring
advanced therapies including left ventricular assist devices or
cardiac transplantation were excluded. Patients with barriers
precluding them from obtaining monitored data (eg, wearable
defibrillator use preventing ballistocardiograph sensing) were
also excluded.
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Textbox 1. Inclusion and exclusion criteria.
Inclusion criteria
•

Age≥18 years

•

HF (heart failure) hospitalization or emergency department visit in last 12 months

•

HF with reduced ejection fraction: most recent left ventricular ejection fraction (LVEF) of <50% and at least 1 recorded LVEF of <40%

•

New York Heart Association Functional Class II-IV

•

Sleeps in same bed ≥4 days per week

•

Ambulatory

•

Willingness to complete the required surveys, measurements, and study activities

Exclusion criteria
•

Advanced HF therapies: inotrope therapy, left ventricular assist device or cardiac transplantation

•

Wearable defibrillator or other worn device that may affect ballistocardiogram measurements

•

End-stage renal disease on chronic dialysis

•

Malignancy undergoing active therapy

•

Weight >385 lbs at time of enrollment

•

Living in a skilled nursing facility or other chronic care facility

•

Planned major surgeries or procedures requiring hospitalization in next 6 months

•

Hospice care or life expectancy <1 year

Patients were prospectively screened and recruited from the
Advanced Heart Failure clinic at the Washington University
School of Medicine’s Division of Cardiology. This clinic
specifically treats patients with HF, with a focus on
implementation of GDMTs and evaluation for advanced
therapies including mechanical circulatory assist devices and
cardiac transplantation when indicated. The trial was approved
by the institutional review board at Washington University for
either written or phone-based informed consent. The trial began
recruitment in March 2020.

actions from the patient, optimizing ease-of -use clinical
monitoring platform for clinicians with integration into current
workflows, and data curation through smart triaging to minimize
information overload for the clinical teams.
The RPM platform (Figure 1):
•

Ethical Considerations
The trial was approved by the ethics review board of the
Washington University Office of Ethics and Integrity, with all
information for patient informed consent reviewed. The trial
was deemed to be in equipoise with current standard of care for
heart failure management.

•

RPM Platform
The RPM platform for the trial was provided by a third-party
vendor, Myia Health (San Francisco, CA). The platform consists
of patient biometric sensors, a digital “Home Hub” tablet to
aggregate data from the sensors and transmit to the vendor for
analysis, and a web-based clinical interface for clinicians to
review data. The clinical interface was co-designed with the
advanced HF clinicians to incorporate clinician priorities in its
design. To ensure that the RPM platform was optimally designed
for clinician and patient needs, Myia conducted clinician and
patient interviews (n=51), and incorporated their input into the
design of the RPM platform (Figure 1). These interviews
identified the following priorities for the prospective RPM
platform: home sensors that collected data with minimal or no
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•

Patient biometric sensors: Sensors include a weight scale,
BP cuff, and a ballistocardiograph. The ballistocardiograph
is a pressure-based sensor that is placed under a patient’s
bed mattress. It measures ballistic forces related to heart
and lung movement to derive heart rate (HR), respiratory
rate (RR), and other associated physiologic parameters.
Importantly, the ballistocardiograph is always “on” and
only requires the patient to lie in bed to collect data, thus
minimizing the data collection burden for patients.
Home Hub tablet: An Android (Google) LTE-enabled tablet
loaded with the Myia application serves as a data
aggregation and transmission point for collected vital sign
sensor data. It also includes a user interface to solicit,
collect, and transmit patient-reported outcomes.
Clinical interface: The clinician interface displays sensor
data for all patients currently enrolled in the trial. The
interface includes a data visualization workspace that
juxtaposes longitudinal health data (vital signs, symptoms)
with event data (ED visits, hospitalizations) to aid in clinical
management. Patient data is prioritized for clinical review
using alerts. Alerts are customized based on patient-specific
thresholds (eg, vital signs outside of predefined range), with
deviations outside normal range triggering an alert.
Additionally, among patients on submaximal GDMTs,
medication-specific alerts are included to allow for rapid
HF medication up-titration.
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Figure 1. Remote patient monitoring platform used in the Novel Data Collection and Analytics Tools for Remote Patient Monitoring in Heart Failure
Trial. BP: blood pressure; ECG: electrocardiogram.

Study Protocol
Following enrollment, study participants have the Home Hub
and sensors shipped to their homes. Once the kit is delivered,
the technical support team will reach out to assist with home
monitoring and sensor setup.
As part of the study, patients will take measurements daily from
all study sensors. The first 7 days for each patient will be a
run-in period where patient data is collected. If sufficient data
is collected and transmitted, study participants will transition
to the active management phase. Sufficient data is defined as
transmission from both BP cuff/weight scale and
ballistocardiograph sensors in at least 4 of the 7 days. If
minimum requirements are not met, patients are continued in
the run-in period for an additional week (up to 3 weeks
maximum). Technical support will contact patients to determine
if lack of transmission represents a technical issue versus
nonadherence. If patients were unable to meet minimum data
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requirements after 3 weeks, then they were disenrolled from
the study.
Following run-in period completion, study participants will
enter the 6-month active management phase of the study. A
designated research nurse is responsible for daily monitoring
of the RPM clinical interface. This includes monitoring the
RPM clinical interface daily for clinical alerts, contacting
patients to assess clinical status in response to alerts, and
escalating to the patient’s HF cardiologist if clinical status
warrants management changes. This research nurse will also
be responsible for contacting study participants for issues with
data transmission or poor adherence to patient data collection.
On a monthly basis, enrolled patients will have their clinical
data reviewed by a multidisciplinary team including a triaging
nurse and an HF cardiologist. The purpose of these reviews is
to assess participant’s clinical status and adherence to data
transmissions, and to identify opportunities for optimized
medical management, including maximizing GDMT. RPM
platform monitoring is outlined in Figure 2.
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Figure 2. Remote patient monitoring platform monitoring strategies. BP: blood pressure; GDMT: guideline-directed medical therapy; HF: heart failure;
HR: heart rate.

Clinical Alerts and Thresholds
Several clinical monitoring alerts will be used prospectively
during the management phase of the study. Each alert has default
thresholds that are customizable to individual study participants.
Absolute threshold alerts will be turned on by default in all

patients, while GDMT alerts can be opted-in by the clinical
team for patients deemed to be on submaximal GDMT. Default
values are shown in Textbox 2. All alerts are required to be
addressed within 24 hours by the monitoring nurse and escalated
to the clinical team if indicated. Actions taken by the clinical
team in response to the alerts were documented.

Textbox 2. Remote patient monitoring clinical interface parameters with default values.
Absolute thresholds alerts
High and low thresholds for weight, blood pressure (BP), and heart rate (HR). Thresholds include both default absolute values and patient-specific
deviation from baseline values.
•

•

•

Weight
•

>3 lbs over 1 day

•

>5 lbs over 3 days

BP
•

Systolic blood pressure (SBP)>200 mmHg

•

SBP>180 mmHg each day for 3 consecutive days

•

SBP<80 mmHg

HR
•

HR<35 bpm average in 1 night

•

HR>150 bpm

Guideline-directed medical therapy (GDMT) alerts
These alerts are generated for patients on submaximal GDMT. They are designed to permit rapid up-titration of GDMT, customized based on drug
class.
•

Beta-blocker
•

•

HR>80 bpm (nightly average) and SBP>100 mmHg for 3 consecutive days

Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, angiotensin receptor neprolysin inhibtor, and mineralcorticoid receptor
antagonist
•

SBP>110 for 3 consecutive days
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Outcomes
Trial outcomes were designed to both directly evaluate the
perceived utility of the RPM platform and to assess its impact
on clinical outcomes.
Patient Adherence to Data Collection and Transmission
Patient data collection adherence will be measured for all home
BP cuff, scale, and ballistocardiograph sensors as percentage
of days with data transmission from each device over the
6-month trial duration. “Minimally-useful data profile” is
defined as the percentage of weeks with at least 4 days of data
transmission from both an active (BP cuff or weight scale) and
passive (ballistocardiograph) sensor.
Patient-Perceived Usability and Utility of RPM Platform
Patients’ assessment of the RPM platform utility and usability
will be assessed through a series of surveys (survey timeline in
Multimedia Appendix 1). Surveys will be conducted at 2, 4,
and 6 months. Surveys will have scaled numerical responses 1
to 7, with 17 total questions. Questions will assess RPM
platform components (scale, BP cuff, ballistocardiograph)
usability, platform setup, and the platform’s perceived utility
in augmenting clinical care. The sum of the numeric responses
for each question will combine into an “overall utility score.”
This score will be assessed for change throughout the study
duration for each participant. Surveys will be reviewed at the
time of submission by the research nursing group. Patients will
be contacted regarding any significant RPM platform concerns.
Scores will also be analyzed to assess for RPM platform
strengths/weaknesses and to evaluate for change in perceived
utility over the trial duration.
Clinician-Perceived Usability and Utility of RPM Platform
Along with patients, clinicians will also be assessing the RPM
platform’s utility and usability through a series of surveys
(survey timeline in Multimedia Appendix 1). Surveys will be
conducted at 3 and 6 months, with scaled numerical 1 to 7
ratings of 14 components of the RPM platform, with a focus on
the clinical interface.

Bhatia et al
established methodology [10], baseline doses of each of these
drug classes will be the classified percentage of target dose: 0%
to 25%, 25% to 50%, 50% to 75%, and 75% to 100%. This
target dose category will be compared for each participant
between 0 and 6 months to assess for changes in GDMT dosing.
Change in proximity to target dose over trial duration will be
compared to that of matched controls (see “Statistical
Considerations” for matching methodology). For all drug
classes, the absolute number of medication changes will be
recorded and compared to that of the matched controls.
HF Symptoms and Performance Status
Study participants’ symptoms and performance status will be
evaluated using the Kansas City Cardiomyopathy Questionnaire
(KCCQ-12) at 0, 3, and 6 months (Multimedia Appendix 1),
with absolute results and change over study duration reported.
HF Clinical Events
The study’s primary clinical end point is HF hospitalizations.
Secondary clinical events include other unplanned
hospitalizations and ED visits. Clinical events will be obtained
through monthly electronic health record review by the research
team and with monthly patient surveys. All hospitalizations will
be adjudicated by the clinical team as either HF or other
unplanned hospitalizations. Clinical end points will be compared
to those of matched controls.

Statistical Analysis
Patient medication changes and clinical events will be compared
to 100 matched historical controls. Controls will be patients
with HFrEF matched on an HF hospitalization in the past year,
age within 5 years, sex, race, and comorbidities (coronary artery
disease, diabetes mellitus, hypertension, renal disease).
Statistical analysis for clinical end points will be in comparison
with matched controls. For survey data, including RPM platform
utility and patient symptom assessments, these will be evaluated
for change over the trial’s 6-month duration. Continuous
variables will be assessed via sample t tests, and categorical
variables will be assessed via chi-square tests.

Clinical Utility of RPM-Generated Clinical Alerts
The number of absolute threshold clinical alerts (Textbox 2)
generated by the RPM platform will be reported, along with its
accompanying clinical action. Clinical actions include
medication changes (adding/holding medications), scheduling
a follow-up appointment, advising immediate medical care (ED
visit or hospitalization), or no action. The clinical utility of each
absolute threshold alert will be measured as the percentage of
clinical alerts prompting clinical action and categorized by
physiologic measure (ie, weight, BP, and HR).

Power Calculation

Medication Changes
Clinician-directed changes will be tracked during trial duration
for the following HF medication classes: beta-blockers,
angio-converting enzyme (ACE)/angiotensin receptor blocker
(ARB)/angiotensin receptor-neprilysin inhibitors (ARNIs),
magnetic resonance angiographies (MRAs), hydralazine,
nitrates, and loop diuretics. The distance to target dose will also
be assessed for GDMT medications, beta-blocker,
ACE/ARB/ARNI, and MRA drug classes. Based on previously

HF Symptoms and Performance Status
This trial is powered at 84% to assess for a 6-point increase (SD
20) in KCCQ scores for trial participants over the trial duration.
We will use a type I error of 0.05. This improvement in KCCQ
scores was based on the Minnesota Living with Heart Failure
symptom assessments improvements observed in the
CHAMPION trial [19].
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Medication Changes
This trial is powered at 99% to assess for 50% more medication
changes in the study arm compared to historical controls. We
will use a type I error of 0.05, assuming Poisson distribution
[17]. This medication change rate was selected based on prior
work in the CHAMPION trial, in which monitored patients had
over double the number of medication changes (n=2468 for 270
patients vs n=1061 for 280 patients; P<.001) [18].
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HF Hospitalizations
Regarding HF hospitalizations, Nov-HF-RPM is underpowered
for this end point. Power calculation for clinical HF events was
conducted using the baseline event rates observed in the
CHAMPION trial given similar inclusion criteria [19]. Effect
size was estimated to be roughly 50% that observed with
CardioMEMS. Using type 1 error of 0.05, the study would
require 1054 recruited patients (with 1054 matched controls)
to obtain 80% power. We will nonetheless plan to collect this
clinical end point to better understand if there is a positive trend
with RPM. Future studies with larger patient populations will
be required to obtain adequate statistical power for
hospitalizations.

Results
This prospective trial began enrollment in March 2020 and
anticipates enrollment completion by June 2022, with trial
completion by December 2022.

Discussion
Optimal HF care requires the ability to effectively monitor and
treat impending clinical decompensation so as to prevent ED
visits and hospitalizations. RPM aims to address the current
gaps in outpatient clinical care. To date, the only RPM strategy
using an invasive hemodynamic sensor (CardioMEMS) has
demonstrated the ability to reduce HF hospitalizations [11].
RPM strategies using noninvasive biometric sensors are a
potential lower risk and lower cost approach to RPM. However,
prior trials evaluating noninvasive approaches to RPM have not
demonstrated clinical efficacy [12,20].
Several limitations of noninvasive RPM strategies are thought
to contribute to the lack of demonstrated efficacy in these prior
studies. These include poor patient adherence to monitoring, a
lack of clinically actionable patient data and alerts, and a lack
of clinical buy-in. The design of the Nov-RPM-HF study seeks
to overcome these limitations.
Poor patient data collection adherence was observed in the
majority of noninvasive RPM clinical trials and is thought to
have contributed to neutral outcomes [12]. Both
patient-perceived utility and ease-of-use of RPM platforms are

Bhatia et al
believed to be contributing factors to nonadherence.
Accordingly, Nov-HF-RPM will assess if improved adherence
can be observed through the use of passive sensors for patient
data collection that do not require direct patient action. The trial
will also directly compare data collection adherence between
passive (ballistocardiograph) and active sensors (BP cuff, scale).
The ballistocardiograph adds a novel component to the home
sensor collection, with the potential to augment adherence and
provide continuous nightly data for HR and RR. To date, several
studies using ballistocardiograph data-derived algorithms have
demonstrated the ability to effectively classify compensated
versus decompensated disease states in HF [21,22]. However,
the role of the ballistocardiograph in an HF management strategy
has not been studied.
A lack of clinically actionable RPM alerts has been commonly
observed in prior noninvasive RPM studies. A systematic review
of noninvasive RPM trial clinical alerts revealed patients were
contacted only 39% (range 29%-52%) for follow-up and
management changes [14]. Furthermore, RPM alerts with high
false-positive rates have previously led to unnecessary office
visits and hospitalizations [23]. Nov-RPM-HF will assess
clinical utility of all absolute threshold alerts based on if there
is a corresponding clinical action. Alert utility will be broken
down by alert type (weight, BP, HR) to assess comparative
utility of each physiologic measure.
Although seldom measured in RPM clinical trials, adoption and
buy-in from the clinical team is essential for maximal and
effective RPM use. Factors affecting clinical adoption include
perceived utility of RPM-provided patient data and integration
into existing clinical workflows [15]. Nov-RPM-HF evaluates
a clinician-designed RPM platform, and clinical utility will be
assessed through structured surveys, broken down by RPM
platform components, and evaluation of clinical actions
motivated by RPM alerts.
Nov-RPM-HF will provide an important contribution to the
field of RPM for patients with HFrEF. Its design attempts to
overcome prior limitations of prior RPM strategies and
determine its impact on patient engagement and satisfaction,
clinical satisfaction, and HF medical optimization. Insights from
the study will inform the future role of noninvasive RPM as a
viable HF clinical management strategy.
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ED: emergency department
GDMT: guideline-directed medical therapy
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HR: heart rate
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Nov-RPM-HF: Novel Data Collection and Analytics Tools for Remote Patient Monitoring in Heart Failure
RPM: remote patient monitoring
RR: respiratory rate

Edited by G Eysenbach; submitted 12.08.21; peer-reviewed by A Miranda, B Eapen; comments to author 14.10.21; revised version
received 05.12.21; accepted 08.12.21; published 30.06.22
Please cite as:
Bhatia A, Ewald G, Maddox T
The Novel Data Collection and Analytics Tools for Remote Patient Monitoring in Heart Failure (Nov-RPM-HF) Trial: Protocol for
a Single-Center Prospective Trial
JMIR Res Protoc 2022;11(6):e32873
URL: https://www.researchprotocols.org/2022/6/e32873
doi: 10.2196/32873
PMID:

©Ankit Bhatia, Gregory Ewald, Thomas Maddox. Originally published in JMIR Research Protocols
(https://www.researchprotocols.org), 30.06.2022. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The
complete bibliographic information, a link to the original publication on https://www.researchprotocols.org, as well as this
copyright and license information must be included.

https://www.researchprotocols.org/2022/6/e32873

XSL• FO
RenderX

JMIR Res Protoc 2022 | vol. 11 | iss. 6 | e32873 | p. 9
(page number not for citation purposes)

